Lee Ainslie Verona Pharma PLC Transaction History
Maverick Capital LTD
- $5.84 Billion
- Q2 2025
A detailed history of Lee Ainslie (Maverick Capital LTD) transactions in Verona Pharma PLC stock. As of the latest transaction made, Maverick Capital LTD holds 521,859 shares of VRNA stock, worth $55.7 Million. This represents 0.85% of its overall portfolio holdings.
Number of Shares
521,859
Previous 1,783,498
70.74%
Holding current value
$55.7 Million
Previous $113 Million
56.41%
% of portfolio
0.85%
Previous 2.23%
Shares
7 transactions
Others Institutions Holding VRNA
# of Institutions
322Shares Held
76.8MCall Options Held
977KPut Options Held
3.12M-
Janus Henderson Group PLC London, X06.13MShares$655 Million0.3% of portfolio
-
Perceptive Advisors LLC New York, NY5.51MShares$588 Million22.87% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y94.13MShares$441 Million16.48% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.38MShares$361 Million16.88% of portfolio
-
Rtw Investments, LP New York, NY3.05MShares$326 Million4.43% of portfolio
About Verona Pharma plc
- Ticker VRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,954,200
- Market Cap $6.51B
- Description
- Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...